<DOC>
	<DOCNO>NCT01654497</DOCNO>
	<brief_summary>The purpose study try determine maximum safe dose dexanabinol administer people brain cancer . Other purpose study : - find effect ( good bad ) dexanabinol ; - see much drug get body collect blood cerebrospinal fluid use pharmacokinetic ( PK ) study ; - learn dexanabinol might affect growth cancer cell ; - look biomarkers ( biochemical feature use measure progress disease effect drug ) .</brief_summary>
	<brief_title>Dexanabinol Patients With Brain Cancer</brief_title>
	<detailed_description>Protection apoptosis key survival factor cancer cell . Dexanabinol investigation novel anti-cancer therapy base tumoricidal activity observe vitro vivo , presumably due inhibitory activity NFĸB , TNFα , COX-2 additional putative target suck HAT , FAT cyclin dependent kinase . Targeted induction apoptosis cancer cell versus normal cell provide attractive strategy treatment brain cancer , pernicious disease debilitate neurological side effect poor prognosis . A single intravenous dose dexanabinol demonstrate safety human . Therefore , conduct phase I dose escalation study examine safety multiple dose dexanabinol drug penetration brain , determine suitable dose move phase II trial efficacy .</detailed_description>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>HU 211</mesh_term>
	<mesh_term>Dronabinol</mesh_term>
	<criteria>Histologically radiologically confirm diagnosis brain cancer : glioblastoma ( GBM ) , anaplastic astrocytoma ( AA ) , anaplastic oligodendroglioma ( AO ) , anaplastic mixed oligoastrocytoma ( AMO ) , low grade glioma , brain metastasis , meningioma , leptomeningeal metastasis Has fail prior standard therapy include maximal safe surgical resection , radiation therapy ( appropriate specific cancer type ) , systemic therapy . For diagnosis GBM : undergone least one prior surgical grosstotal subtotal tumor resection , course postoperative radiation therapy concurrent temozolomide , least 2 cycle maintenance temozolomide . For diagnosis meningioma : option standard therapy surgical resection ( partial total resection ) radiation . Has progression brain cancer measurable disease magnetic resonance imaging ( MRI ) compute tomography ( CT ) scan . Age ≥ 18 year . Karnofsky Performance Status ≥ 60 % . ( Appendix A ) . Subjects must life expectancy equal great 8 week . Organ Marrow Function Requirements Hematology : Absolute Neutrophil Count ( ANC ) ≥ 1.5 x 109/L Platelet count ≥ 100 x 109/L Hemoglobin ≥ 9.0 g/dL White blood cell ( WBC ) count ≥ 3.0 x 109/L Biochemistry : AST/SGOT ALT/SGPT ≤ 2.5 x institution 's ULN Total bilirubin ≤ 1.5 x institution 's ULN Serum creatinine ≤ 1.5 x institution 's ULN 24hour creatinine clearance ≥ 50 ml/min Alkaline phosphatase ( ALP ) ≤ 2.5 x ULN unless consider tumor relate Estimated GFR &gt; 50 ml/min ( base Wright formula ) Coagulation : INR &lt; 1.5 x institution 's ULN PT/aPTT within institution 's normal range , unless receive therapeutic low molecular weight heparin Contraception Woman childbearing potential man partner childbearing potential agrees use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry , duration study participation , 30 day follow completion therapy . Woman childbearing potential negative pregnancy test initiation study drug dose . Current anticipated use investigational agent . Current anticipated use enzymeinducing antiepileptic drug ( EIAED ) . Insufficient time recovery prior therapy : le 28 day investigational agent , less 28 day prior cytotoxic therapy ( except 23 day prior temozolomide , 14 day vincristine , 42 day nitrosoureas , 21 day procarbazine administration ) , less 7 day noncytotoxic agent , e.g. , interferon , tamoxifen , thalidomide , cisretinoic acid , etc . ( radiosensitizer count ) . Less 4 week surgery insufficient recovery surgicalrelated trauma wound healing . History allergic reaction attribute compound similar chemical biologic composition dexanabinol . History allergic reaction medicine contain polyoxyethylated castor oil control premedications . Severe uncontrolled medical disorder would , investigator 's opinion , impair ability receive study treatment ( i.e. , uncontrolled diabetes , chronic renal disease , chronic pulmonary disease active , uncontrolled infection ) . Electrolyte abnormality correct normal level prior initiate study drug . Known diagnosis human immunodeficiency virus ( HIV ) infection . Impaired cardiac function include follow : Congenital long QT syndrome know family history long QT syndrome ; History presence clinically significant ventricular atrial tachyarrhythmias Clinically significant rest bradycardia ( &lt; 50 beat per minute ) Inability monitor QT interval ECG QTc &gt; 450 msec baseline ECG . If QTc &gt; 450 electrolyte within normal range , electrolyte correct patient rescreened QTc Myocardial infarction within 1 year start study drug Other clinically significant heart disease ( e.g. , unstable angina , congestive heart failure , uncontrolled hypertension ) Pregnant nursing . There potential congenital abnormality regimen harm nursing infant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Brain</keyword>
	<keyword>Glioma</keyword>
	<keyword>glioblastoma</keyword>
	<keyword>metastasis</keyword>
	<keyword>cancer</keyword>
	<keyword>ETS2101</keyword>
	<keyword>leptomeningeal</keyword>
	<keyword>astrocytoma</keyword>
	<keyword>oligodendroglioma</keyword>
	<keyword>meningioma</keyword>
</DOC>